FDA Approves AEMCOLO™ (rifamycin), the First Antibiotic Approved for the Treatment of Travelers’ Diarrhea in Over a Decade
FDA Grants Cosmo Pharmaceuticals both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX®) for Travelers’ Diarrhea
Upon FDA Approval, Aries Pharmaceuticals, Inc. to Lead U.S. Commercial Efforts
MB MMX™ is a first-in-class drug candidate based on Cosmo Pharmaceuticals’ proprietary MMX delivery
Aries Pharmaceuticals and Olympus Initiate Co-Promotion of Eleview™ at the American College of Gastroenterology’s World Congress
Aries Pharmaceuticals, Inc. enters co-promotion agreement in the U.S. with Olympus for Eleview™.
Aries Pharmaceuticals, Inc. Shares Positive Results for Clinical Study of Eleview™ at Digestive Disease Week Annual Meeting
Novel Development in Submucosal Injection Agents Elevates Lesions to Facilitate Removal